📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Cellestia

1.1 - Company Overview

Cellestia Logo

Cellestia

Headquarter: Switzerland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage R&D therapies to control and modulate pathogenic gene expression via selective inhibition of transcription factors in the cell nucleus. Lead candidate CB-103 targets the CSL-NOTCH complex and is in Phase 2 for various cancers and GvHD, showing efficacy in multi-drug resistant cancers and autoimmune diseases. Pipeline includes preclinical assets for psoriasis, Sjogren’s, SLE, IBD and giant cell arteritis.

Products and services

  • CB-103: A clinical-stage drug candidate inhibiting the CSL-NOTCH transcription complex, showing efficacy in multi-drug resistant cancers and autoimmune diseases
  • Phase 2 trials ongoing in multiple cancer types and GvHD
  • Selective transcription factor inhibition approach: A nucleus-targeted program that architects therapies to modulate pathogenic gene expression across diseases by selective inhibition of transcription factors within the cell nucleus
  • Pre-clinical candidates: Preclinical pipeline assets targeting psoriasis, Sjogren’s syndrome, systemic lupus erythematosus, inflammatory bowel disease, and giant cell arteritis
  • IND-enabling and First-in-Human studies planned within 12–18 months.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Cellestia

VisionGate Logo

VisionGate

HQ: United States Website
  • Description: Provider of an automated 3D cell imaging platform for early cancer detection and prevention.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full VisionGate company profile →
Arc Medical Logo

Arc Medical

HQ: United Kingdom Website
  • Description: Provider of award-winning, innovative medical products designed to increase Adenoma Detection Rates (ADR) and improve retrieval methods, focusing on enhancing physician experience and patient outcomes with cost effectiveness.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Arc Medical company profile →
Nerio Therapeutics Logo

Nerio Therapeutics

HQ: United States Website
  • Description: Provider of biotechnology for the life sciences sector; founded in 2019 and based in La Jolla, CA, USA.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Nerio Therapeutics company profile →
CG Oncology Logo

CG Oncology

HQ: United States Website
  • Description: Provider of clinical-stage oncolytic immunotherapies targeting cancer, centered on the investigational agent cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Activities include Phase 3 trials BOND-003 (monotherapy in high-risk BCG-unresponsive NMIBC) and PIVOT-006 (intermediate-risk NMIBC), and the Phase 2 CORE-001 combination with pembrolizumab in high-risk BCG-unresponsive NMIBC.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CG Oncology company profile →
Endocare Logo

Endocare

HQ: United States Website
  • Description: Provider of medical devices and related consumables for cryoablation, developing, manufacturing, and distributing these products.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Endocare company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Cellestia

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Cellestia

2.2 - Growth funds investing in similar companies to Cellestia

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Cellestia

4.2 - Public trading comparable groups for Cellestia

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Cellestia

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Cellestia

What does Cellestia do?

Cellestia is a provider of clinical-stage R&D therapies to control and modulate pathogenic gene expression via selective inhibition of transcription factors in the cell nucleus. Lead candidate CB-103 targets the CSL-NOTCH complex and is in Phase 2 for various cancers and GvHD, showing efficacy in multi-drug resistant cancers and autoimmune diseases. Pipeline includes preclinical assets for psoriasis, Sjogren’s, SLE, IBD and giant cell arteritis.

Who are Cellestia's competitors?

Cellestia's competitors and similar companies include VisionGate, Arc Medical, Nerio Therapeutics, CG Oncology, and Endocare.

Where is Cellestia headquartered?

Cellestia is headquartered in Switzerland.

How many employees does Cellestia have?

Cellestia has 1,000 employees 🔒.

When was Cellestia founded?

Cellestia was founded in 2010 🔒.

What sector and industry vertical is Cellestia in?

Cellestia is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Cellestia

Who are the top strategic acquirers in Cellestia's sector and industry

Top strategic M&A buyers and acquirers in Cellestia's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Cellestia?

Top strategic M&A buyers groups and sectors for Cellestia include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Cellestia's sector and industry vertical

Which are the top PE firms investing in Cellestia's sector and industry vertical?

Top PE firms investing in Cellestia's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Cellestia's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Cellestia's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Cellestia's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Cellestia include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Cellestia's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Cellestia?

The key public trading comparables and valuation benchmarks for Cellestia include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Cellestia for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Cellestia with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Cellestia's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Cellestia with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Cellestia's' sector and industry vertical?

Access recent funding rounds and capital raises in Cellestia's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Cellestia